Articles from PURE Bioscience, Inc.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, is proud to announce an innovative application method for membrane treatment in the dairy and beverage industry using our flagship product, PURE® Hard Surface. This groundbreaking solution addresses common membrane fouling and sanitization challenges, delivering outstanding results that enable operators to restore throughput and sanitize the membrane without damage or oxidation.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2025.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and Hydrite Chemical Company (“Hydrite”) have entered into a multi-year distribution agreement for the purchase and selling of SDC products under special terms and conditions.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2024.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and branded by Greenville (“bbG”), is excited to announce the official start of an extensive rebranding campaign to renew its corporate vision. This rebranding initiative aims to strengthen the Company’s identity and culture in the market and to better reflect its commitment to cutting-edge scientific advancements in antimicrobials and disinfection to serve the food and beverage industry.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and AFCO, a Zep Company (“AFCO”), have entered into a multi-year distribution agreement for the purchase and selling of SDC products under special terms and conditions.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and Quip Laboratories, Inc. (“Quip Labs”), have entered into a multi-year distribution agreement for the purchase and selling of SDC products under special terms and conditions.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2024.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and Madison Chemical Co., Inc. (“Madison Chemical”), have entered into a multi-year distribution agreement for the purchase and selling of SDC products under special terms and conditions.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), has entered into a multi-year distribution agreement with Tennessee-based Zee Company to purchase and sell PURE’s patented antimicrobial products. This agreement will allow PURE, the non-toxic Silver Dihydrogen Citrate (SDC) antimicrobial creator, to purchase and sell its SDC products to Zee Company and its clients under special terms and conditions.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and ChemStation Buyers Association, Inc. (“ChemStation”), have entered into a multi-year distribution agreement for the purchase and selling of SDC products under special terms and conditions.

PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, is set to unveil its newest food safety solutions at the 2024 International Association for Food Protection (IAFP) show in Long Beach, California on July 14th-17th, 2024.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and AgroVet Alliance, FZE (“AVA”), have entered into a multi-year international supply and license agreement for the purchase and selling of SDC products under special terms and conditions.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2024.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported the appointment of Darin Zehr to its Board of Directors, effective as of May 1, 2024.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2024.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2023.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2023.

PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, is set to unveil its “PURE Genius” food safety program at the 2023 International Association for Food Protection (IAFP) show in Toronto, Ontario, Canada on July 16th-19th, 2023.

PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter and six-month period ended January 31, 2023.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2022.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2022.

PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2022.

PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter and six-month period ended January 31, 2022.

PURE Bioscience, Inc. (OTCQB: PURE) (the “Company,” “PURE” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2021.

PURE Bioscience, Inc. (OTCQB: PURE) (the “Company,” “PURE” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2021.

PURE Bioscience, Inc. (OTCQB: PURE) (the “Company,” “PURE” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2021.